Drug intelligence / Profile preview

ART10

Development stage: Preclinical
Lead developer: Arnatar Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

ART10 is an antisense oligonucleotide (ASO) therapeutic candidate being developed by Arnatar Therapeutics for the treatment of metabolic diseases. Utilizing Arnatar's proprietary ACT-UP1 platform, ART10 is designed to upregulate the expression of hepatocyte nuclear factor 4-alpha (HNF4A) to restore its function. The program is currently in the discovery stage of development.

Targets

HNF4A (Hepatocyte nuclear factor 4 alpha)

Beyond the preview

Go deeper on ART10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART10.

Explore the full profile